[논문]Efficacy and Safety of Oxaliplatin, 5-Fluorouracil, and Folinic Acid Combination Chemotherapy as First-Line Treatment in Metastatic or Recurrent Gastric Cancer

Kim, Han Jo; Eun, Jun Young; Jeon, Young Woo; Yun, Jina; Kim, Kyoung Ha; Kim, Se Hyung; Kim, Hyun Jung; Lee, Sang-Cheol; Bae, Sang Byung; Kim, Chan Kyu; Lee, Nam Su; Lee, Kyu Taek; Park, Seong-Kyu; Won, Jong-Ho; Hong, Dae Sik; Park, Hee Sook

doi:10.4143/crt.2011.43.3.154

Efficacy and Safety of Oxaliplatin, 5-Fluorouracil, and Folinic Acid Combination Chemotherapy as First-Line Treatment in Metastatic or Recurrent Gastric Cancer 원문보기

Cancer research and treatment : official journal of Korean Cancer Association, v.43 no.3, 2011년, pp.154 - 159

Kim, Han Jo (Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea.) , Eun, Jun Young (Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea.) , Jeon, Young Woo (Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea.) , Yun, Jina (Divisions of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.) , Kim, Kyoung Ha (Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.) , Kim, Se Hyung (Divisions of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.) , Kim, Hyun Jung (Divisions of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.) , Lee, Sang-Cheol (Division of Hematology and Oncology, D) , Bae, Sang Byung , Kim, Chan Kyu , Lee, Nam Su , Lee, Kyu Taek , Park, Seong-Kyu , Won, Jong-Ho , Hong, Dae Sik , Park, Hee Sook

Abstract ▼ AI-Helper

PurposeWe retrospectively determined the efficacy and safety of the combination of oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) as first-line chemotherapy for patients with metastatic or recurrent gastric cancer.Materials and MethodsBetween January 2006 and August 2009, 39 patients with histologically-confirmed, metastatic or recurrent gastric cancer underwent chemotherapy, and the results were retrospectively investigated. The chemotherapy regimen consisted of oxaliplatin (100 mg/m2) and FA (200 mg/m2; 2-hour infusion), then 5-FU (2,400 mg/m2; 46-hour continuous infusion) every 2 weeks.ResultsThirty-nine patients received a total of 210 treatment cycles. The median number of cycles was 6 (range, 1 to 16). Of the 32 evaluable patients, zero patients achieved a complete response and 11 patients achieved a partial response (response rate, 28.2%). The median time-to-progression and overall survival were 4.3 months (95% confidence interval [CI], 2.0 to 6.5 months) and 9.8 months (95% CI, 3.5 to 16.0 months), respectively. The main hematologic toxicity was anemia, which was observed in 119 cycles (56.7%). Grade 3/4 neutropenia was observed in 32 cycles (15.2%). The main non-hematologic toxicity was constipation, which was observed in 91 cycles (46.2%). Peripheral neuropathy occurred in 71 cycles (33.8%); all cases were grade 1 or 2. No treatment-related deaths were reported.ConclusionThis study showed that combination chemotherapy with oxaliplatin, 5-FU, and FA is an active and well-tolerated regimen as first-line treatment in patients with metastatic or recurrent gastric cancer.

주제어

참고문헌 (22)

1 Pisters PW Kelsen DP Powell SM Tepper JE De Vita VT Jr Hellman S Rosenberg SA Cancer of the stomach Cancer: principles and practice of oncology 2005 7th ed Philadelphia, PA Lippincott Williams & Wilkins 909 944
2 Glimelius B Ekström K Hoffman K Graf W Sjödén PO Haglund U Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 1997 8 163 168 9093725

상세보기
3 Ohtsu A Chemotherapy for metastatic gastric cancer: past, present, and future J Gastroenterol 2008 43 256 264 18458840
4 Waters JS Norman A Cunningham D Scarffe JH Webb A Harper P Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial Br J Cancer 1999 80 269 272 10390007

상세보기
5 Vanhoefer U Rougier P Wilke H Ducreux MP Lacave AJ Van Cutsem E Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J Clin Oncol 2000 18 2648 2657 10894863
6 Arnould S Hennebelle I Canal P Bugat R Guichard S Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines Eur J Cancer 2003 39 112 119 12504667

상세보기
7 Marchetti P Galla DA Russo FP Ricevuto E Flati V Porzio G Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line Anticancer Res 2004 24 219 226 15015600

상세보기
8 Ravaioli A Marangolo M Pasquini E Rossi A Amadori D Cruciani G Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer J Clin Oncol 2002 20 2545 2550 12011134

상세보기
9 Extra JM Espie M Calvo F Ferme C Mignot L Marty M Phase I study of oxaliplatin in patients with advanced cancer Cancer Chemother Pharmacol 1990 25 299 303 2295116

상세보기
10 Woynarowski JM Faivre S Herzig MC Arnett B Chapman WG Trevino AV Oxaliplatin-induced damage of cellular DNA Mol Pharmacol 2000 58 920 927 11040038

상세보기
11 Schmidt W Chaney SG Role of carrier ligand in platinum resistance of human carcinoma cell lines Cancer Res 1993 53 799 805 8428361

상세보기
12 Mamenta EL Poma EE Kaufmann WK Delmastro DA Grady HL Chaney SG Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines Cancer Res 1994 54 3500 3505 8012973

상세보기
13 Cunningham D Starling N Rao S Iveson T Nicolson M Coxon F Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 2008 358 36 46 18172173

상세보기
14 Al-Batran SE Hartmann JT Probst S Schmalenberg H Hollerbach S Hofheinz R Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie J Clin Oncol 2008 26 1435 1442 18349393

상세보기
15 Louvet C André T Tigaud JM Gamelin E Douillard JY Brunet R Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients J Clin Oncol 2002 20 4543 4548 12454110

상세보기
16 Al-Batran SE Atmaca A Hegewisch-Becker S Jaeger D Hahnfeld S Rummel MJ Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer J Clin Oncol 2004 22 658 663 14966088

상세보기
17 Kim DY Kim JH Lee SH Kim TY Heo DS Bang YJ Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer Ann Oncol 2003 14 383 387 12598342

상세보기
18 Chao Y Yeh KH Chang CJ Chen LT Chao TY Wu MF Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer Br J Cancer 2004 91 453 458 15226770

상세보기
19 Lordick F Lorenzen S Stollfuss J Vehling-Kaiser U Kullmann F Hentrich M Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer Br J Cancer 2005 93 190 194 16012522

상세보기
20 Therasse P Arbuck SG Eisenhauer EA Wanders J Kaplan RS Rubinstein L New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 2000 92 205 216 10655437
21 Choi IS Oh DY Kim BS Lee KW Kim JH Lee JS Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer Cancer Res Treat 2007 39 99 103 19746224

상세보기
22 Extra JM Marty M Brienza S Misset JL Pharmacokinetics and safety profile of oxaliplatin Semin Oncol 1998 25 2 Suppl 5 13 22 9609104

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Efficacy and Safety of Oxaliplatin, 5-Fluorouracil, and Folinic Acid Combination Chemotherapy as First-Line Treatment in Metastatic or Recurrent Gastric Cancer 원문보기

Abstract ▼ AI-Helper

주제어

참고문헌 (22)

이 논문을 인용한 문헌

관련 콘텐츠

원문 보기

원문 URL 링크

오픈액세스(OA) 유형

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트